Purine Derivatives A2A Receptor Agonists Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases often have side effects and do not adequately control leukocyte recruitment and activation, leading to tissue damage, and existing adenosine A2A receptor agonists may have limitations in selectivity and cardiovascular effects.
Innovation Solution
Development of novel compounds that are potent agonists of the adenosine A2A receptor with enhanced selectivity over other receptor subtypes, high binding to human serum albumin, and reduced cardiovascular effects, which inhibit leukocyte recruitment and activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing adenosine A2A receptor agonists are used to treat inflammatory diseases, then anti-inflammatory action is achieved, but selectivity over other receptor subtypes is limited and cardiovascular side effects occur
Solution Approach 1:
The patent modifies molecular parameters of adenosine A2A receptor agonists by introducing specific substituents at defined positions on the purine ring system. This changes the pharmacological properties to achieve greater selectivity for A2A receptors over other adenosine receptor subtypes (A1, A2B, A3), thereby reducing off-target cardiovascular effects while maintaining anti-inflammatory activity
Solution Approach 2:
The invention divides the molecule into distinct functional segments: a purine core structure (providing A2A receptor binding), specific substituent groups at defined positions (enhancing selectivity), and stereochemical configurations (optimizing pharmacokinetic properties). This segmentation allows independent optimization of selectivity and safety profiles
2Reliability
If current treatments for inflammatory diseases are used, then some anti-inflammatory effect is achieved, but leukocyte recruitment and activation are not adequately controlled leading to tissue damage
Solution Approach 1:
The patent employs adenosine A2A receptor agonists as intermediary molecules that mediate the anti-inflammatory effect by activating endogenous protective mechanisms. These compounds bind to A2A receptors on leukocytes and vascular endothelium, triggering signaling cascades that inhibit leukocyte recruitment, adhesion, and activation, thereby preventing tissue damage without directly attacking inflammatory mediators
3Power
If compounds with high A2A receptor activity are developed, then anti-inflammatory action is enhanced, but binding to human serum albumin may increase affecting pharmacokinetics
Solution Approach 1:
The patent optimizes the balance between pharmacological activity and pharmacokinetic properties by carefully selecting substituent types and positions. Specific hydrophobic and hydrophilic groups are introduced to modulate both A2A receptor binding affinity (enhancing activity) and human serum albumin binding (affecting distribution and half-life), achieving an optimal compromise for therapeutic efficacy
Data Source
AI summary
The invention relates to novel adenosine receptor agonists of formula (I), methods for their manufacture and their use as medicaments.